HoffmanR.M., StoneS.N., EspeyD., PotoskyA.L.Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. BMC Cancer, 2005; 5:27.
2.
WelchH.G., AlbertsenP.C.Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst, 2009; 101(19):1325–1329.
3.
WiltT.J., MacDonaldR., RutksI., ShamliyanT.A., TaylorB.C., KaneR.L.Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med, 2008; 148(6):435–448.
4.
GreeneK.L., AlbertsenP.C., BabaianR.J., CarterH.B., GannP.H., HanM., et al.Prostate specific antigen best practice statement: 2009 update. J Urol, 2009; 182(5):2232–2241.
5.
WolfA.M., WenderR.C., EtzioniR.B., ThompsonI.M., D’AmicoA.V., VolkR.J., et al.American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin, 2010; 60(2):70–98.
ChouR., CroswellJ.M., DanaT., BougatsosC., BlazinaI., FuR., et al.Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med, 2011; 155(11):762–771.
8.
AndrioleG.L., CrawfordE.D., GrubbR.L.3rd, BuysS.S., ChiaD., ChurchT.R., et al.Mortality results from a randomized prostate-cancer screening trial. N Engl J Med, 2009; 360(13):1310–1319.
9.
HugossonJ., CarlssonS., AusG., BergdahlS., KhatamiA., LoddingP., et al.Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol, 2010; 11(8):725–732.
10.
KjellmanA., AkreO., NormingU., TornblomM., GustafssonO.15-year followup of a population based prostate cancer screening study. J Urol, 2009; 181(4):1615–1621: discussion 1621.
11.
LabrieF., CandasB., CusanL., GomezJ.L., BélangerA., BrousseauG., et al.Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate, 2004; 59(3):311–318.
12.
SandblomG., VarenhorstE., RosellJ., LofmanO., CarlssonP.Randomised prostate cancer screening trial: 20 year follow-up. BMJ, 2011; 342:d1539.
13.
SchröderF.H., HugossonJ., RoobolM.J., TammelaT.L., CiattoS., NelenV., et al.Screening and prostate-cancer mortality in a randomized European study. N Engl J Med, 2009; 360(13):1320–1328.
14.
Bill-AxelsonA., HolmbergL., FilénF., RuutuM., GarmoH., BuschC., et al.Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst, 2008; 100(16):1144–1154.
15.
Bill-AxelsonA., HolmbergL., RuutuM., GarmoH., StarkJ.R., BuschC., et al.Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med, 2011; 364(18):1708–1717.
16.
WiltT.J., BrawerM.K., BarryM.J., JonesK.M., KwonY., GingrichJ.R., et al.The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials, 2009; 30(1):81–87.
17.
SandaM.G., DunnR.L., MichalskiJ., SandlerH.M., NorthhouseL., HembroffL., et al.Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med, 2008; 358(12):1250–1261.
18.
JemalA., SiegelR., XuJ., WardE.Cancer statistics, 2010. CA Cancer J Clin, 2010; 60(5):277–300.
19.
IlicD., O’ConnorD., GreenS., WiltT.J.Screening for prostate cancer: an updated Cochrane systematic review. BJU Int, 2011; 107(6):882–891.
20.
CrawfordE.D., GrubbR.3rd, BlackA., AndrioleG.L.Jr., ChenM.H., IzmirlianG., et al.Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol, 2011; 29(4):355–361.
21.
VolkR.J., HawleyS.T., KneuperS., HoldenE.W., StroudL.A., CooperC.P., et al.Trials of decision aids for prostate cancer screening: a systematic review. Am J Prev Med, 2007; 33(5):428–434.
